14 Cambridge biotech investors backing life science founders in 2026

14 investors are actively funding Cambridge biotech companies in 2026. CIC committed £100M+ to University of Cambridge spinouts. Epidarex closed Fund IV at $145M in January 2026. SV Health manages $4B and backed Mestag Therapeutics in March 2026. Here's who's writing checks.

Cambridge's biotech cluster raised $1.3B in the 12 months to October 2024. The cluster sits at the centre of the UK's Golden Triangle alongside Oxford and London. CellCentric secured $220M Series D in 2026 for its multiple myeloma drug.

Epidarex Capital closed Fund IV at $145M in January 2026. CIC manages £600M+ across multiple funds and launched a new £100M opportunity fund in February 2025. Babraham Research Campus hosts the 2026 Accelerate@Babraham cohort with six pre-seed ventures.

Cambridge biotech spinouts raised over $1B in the past year. The University of Cambridge produces more spinouts per year than any other UK university. 78% of Cambridge deep tech spinouts reach Series B.

Set up an Ellty data room with your IP assignments, clinical data, and cap table before approaching Cambridge biotech investors. Most ask for IP ownership documentation in the first meeting.

What is a Cambridge biotech investor?

A Cambridge biotech investor backs therapeutics, medtech, genomics, or healthtech companies with a link to the Cambridge ecosystem. They differ from generalist VCs by expecting IP ownership resolved and a clear regulatory pathway.

Cambridge biotech investors have direct access to University of Cambridge spinout deal flow via CIC, Cambridge Enterprise, and Parkwalk. That combination of university partnerships and clinical networks is unique in the UK.

Most checks run from £30K at Cambridge Enterprise pre-seed to £20M+ at CIC's opportunity fund. Parkwalk bridges the gap between university grant stage and institutional seed with EIS-eligible funds.

See how London biotech investors compare if your team spans both cities. CIC, Syncona, and SV Health all co-invest with London-based life science VCs.

14 Cambridge biotech investors

1. Cambridge Innovation Capital

Cambridge Innovation Capital manages £600M+ across multiple funds and committed £100M+ to University of Cambridge spinouts. They backed Immutrin's $87M Series A in 2025 alongside the Dementia Discovery Fund. CIC launched a £100M opportunity fund in February 2025, anchored by Aviva Investors and British Patient Capital, with up to £20M per investment. Their EIR programme launched in 2026 in partnership with the University of Cambridge.

Use Ellty to share your clinical data and IP assignments with CIC before meetings. Cambridge biotech VCs ask for structured documentation within 24 hours of first contact.

• Recent Deals: Immutrin $87M Series A (2025); BeyondMath $18.5M seed (February 2026); £100M opportunity fund launch (February 2025); EIR programme launch (2026)
• LinkedIn: Cambridge Innovation Capital LinkedIn
• Sector Focus: Biotech, genomics, medtech, AI drug discovery, deep tech
• Stage Focus: Seed to Series B
• Location: Cambridge, UK
• Website: cic.vc

2. Parkwalk Advisors

Parkwalk Advisors manages £450M+ in AUM and is the most active investor in UK university spinouts. They co-invested in Enhanced Genomics' extended Series A with BGF and Meltwind in 2026. Their Cambridge-specific EIS fund backs pre-seed to Series A spinouts from the University of Cambridge. Parkwalk co-invests with CIC, IP Group, and Amadeus on the same Cambridge biotech rounds.

• Recent Deals: Enhanced Genomics Series A extension (2026, with BGF); AccelerComm $15M lead (June 2025); xWatts seed (February 2026); 41 spinout deals in 2024
• LinkedIn: Parkwalk Advisors LinkedIn
• Sector Focus: Cambridge life sciences, genomics, biotech, EIS-eligible
• Stage Focus: Pre-seed to Series A
• Location: London with Cambridge focus
• Website: parkwalk.vc

3. SV Health Investors

SV Health Investors manages $4B in AUM with a 30-year track record in the US and Europe. They backed Mestag Therapeutics' $40M financing in March 2026. Their portfolio includes Artios Pharma ($115M Series D, November 2025) and TRexBio ($50M financing, January 2026). SV Health invests in Cambridge therapeutics, medtech, and digital health companies from their London office.

• Recent Deals: Mestag Therapeutics $40M (March 2026); TRexBio $50M (January 2026); Artios Pharma $115M Series D (November 2025)
• LinkedIn: SV Health Investors LinkedIn
• Sector Focus: Therapeutics, medtech, digital health, oncology
• Stage Focus: Series A to growth
• Location: London and Boston with Cambridge deal flow
• Website: svhealthinvestors.com

4. Epidarex Capital

Epidarex Capital closed Fund IV at $145M in January 2026, backed by the British Business Bank and Strathclyde Pension Fund. They build therapeutics and medical device companies from emerging UK research hubs including Cambridge. The fund will invest in up to 15 companies across oncology, cardiometabolic, autoimmune, and neurological conditions.

• Recent Deals: Fund IV $145M first close (January 2026); Enterprise Therapeutics £26M Series B (co-investor); up to 15 companies mandate
• LinkedIn: Epidarex Capital LinkedIn
• Sector Focus: Oncology, cardiometabolic, autoimmune, neurological
• Stage Focus: Seed to Series A
• Location: Edinburgh, UK and Bethesda, USA with Cambridge deal flow
• Website: epidarex.com

5. Babraham Bioscience Technologies

Babraham Bioscience Technologies manages the Babraham Research Campus, south of Cambridge. Their Accelerate@Babraham 2026 cohort includes six pre-seed ventures including BASE Rx. The top 14 campus companies have a combined market value of £4B+. Accelerate@Babraham has supported 40 companies raising £120M+ in total.

• Recent Deals: Accelerate@Babraham 2026 cohort (6 companies including BASE Rx); 40 companies supported; £120M+ raised by portfolio
• LinkedIn: Babraham Research Campus LinkedIn
• Sector Focus: Early-stage bioscience, drug discovery, genomics
• Stage Focus: Pre-seed
• Location: Cambridge, UK
• Website: babraham.com

6. IQ Capital

IQ Capital raised $400M across Fund IV and Growth Fund II and is Cambridge's most active deep tech VC. Their TechBio portfolio includes companies using AI for drug discovery and genomics. They secured a £50M cornerstone from the British Business Bank for Fund V in January 2026. IQ Capital backs Cambridge biotech founders at the intersection of AI, biology, and hardware.

• Recent Deals: Fund V £50M BBB cornerstone (January 2026); Nu Quantum $60M Series A co-lead (December 2025); $400M raised across Fund IV and Growth Fund II
• LinkedIn: IQ Capital LinkedIn
• Sector Focus: TechBio, AI drug discovery, genomics, deep tech
• Stage Focus: Seed to Series A + growth
• Location: Cambridge and London
• Website: iqcapital.vc

7. Cambridge Enterprise Ventures

Cambridge Enterprise Ventures is the University of Cambridge's own venture fund. Their START 3.0 programme invests £30K in every selected biotech company with no equity taken until external raise. They backed Tenyks ($3.4M seed, 2026) and Trismik (£2.2M pre-seed). Cambridge Enterprise is the first step for researchers commercialising university life science IP.

Read the investment due diligence checklist before applying to Cambridge Enterprise. University funds require the same documentation rigour as commercial VCs.

• Recent Deals: Tenyks $3.4M seed (2026); Trismik £2.2M pre-seed (2026); START 3.0 programme active; £30K per company with no early equity
• LinkedIn: Cambridge Enterprise LinkedIn
• Sector Focus: University of Cambridge biotech, medtech, deep tech spinouts
• Stage Focus: Pre-seed
• Location: Cambridge, UK
• Website: enterprise.cam.ac.uk

8. Syncona

Syncona is a FTSE250 company that founds, builds, and funds healthcare companies in advanced therapeutics. They co-led the £22.5M investment in Cambridge-based Mosaic Therapeutics. Their portfolio focuses on cell and gene therapy, including Autolus and Freeline. Syncona co-invests with CIC and SV Health on Cambridge-originated life science rounds.

• Recent Deals: Mosaic Therapeutics £22.5M co-lead; Autolus portfolio; cell and gene therapy focus; CIC and SV Health co-investment history
• LinkedIn: Syncona LinkedIn
• Sector Focus: Cell and gene therapy, advanced therapeutics, rare diseases
• Stage Focus: Seed to growth
• Location: London with Cambridge deal flow
• Website: synconaltd.com

9. Start Codon

Start Codon is a Cambridge life science venture builder now wholly owned by Cambridge Innovation Capital. They backed HotHouse Therapeutics in December 2025, their most recent investment. The portfolio of 28 companies has raised £50M+ in total. Start Codon is not taking new applications but remains an active investor in its existing portfolio.

• Recent Deals: HotHouse Therapeutics (December 2025); 28 portfolio companies; £50M+ raised; wholly owned by CIC
• LinkedIn: Start Codon LinkedIn
• Sector Focus: Therapeutics, medtech, healthtech, drug discovery
• Stage Focus: Pre-seed to seed (existing portfolio only)
• Location: Cambridge, UK
• Website: cic.vc/startcodon

10. IP Group

IP Group is a specialist investor in science and technology companies spun out from UK universities. They manage Parkwalk Advisors (acquired 2017) and co-invest alongside CIC on Cambridge biotech rounds. Their Cambridge portfolio spans biotech, AI, quantum, and life sciences companies. IP Group is a key structural investor in the Cambridge ecosystem via its Parkwalk subsidiary.

Use Ellty to track which IP Group partners open your spinout documentation. University spinout investors review IP assignment agreements before any first meeting.

• Recent Deals: AccelerComm $15M co-lead (June 2025); Parkwalk parent company; Cambridge biotech spinout mandate
• LinkedIn: IP Group LinkedIn
• Sector Focus: Cambridge biotech, life sciences, quantum, deep tech
• Stage Focus: Seed to growth
• Location: London with Cambridge focus
• Website: ipgroupplc.com

11. Amadeus Capital Partners

Amadeus Capital Partners manages $1.3B+ and was co-founded by Hermann Hauser (ARM co-founder). Their TechBio portfolio includes PolyAI ($86M Series D, December 2025). They back Cambridge biotech founders building at the intersection of AI and biology. Amadeus co-invests with CIC and Parkwalk on Cambridge spinout rounds.

• Recent Deals: PolyAI $86M Series D (December 2025); Cambridge Investor Day 2025 presence; TechBio and AI biotech mandate; $1.3B+ AUM
• LinkedIn: Amadeus Capital Partners LinkedIn
• Sector Focus: TechBio, AI biotech, advanced computing, deep tech
• Stage Focus: Seed to Series C
• Location: Cambridge and London
• Website: amadeuscapital.com

12. British Business Bank

The British Business Bank backed Epidarex Fund IV as cornerstone investor in January 2026. They committed £20M to CIC's Opportunity Fund in February 2025 alongside Aviva Investors. The BBB's patient capital enables several Cambridge-focused funds to operate at scale. They are the most important structural funder in the Cambridge biotech ecosystem.

Read how to prepare for due diligence before tracking multiple government-backed funding applications. Cambridge biotech founders often apply to BBB-backed funds alongside CIC and Parkwalk.

• Recent Deals: Epidarex Fund IV cornerstone (January 2026); CIC Opportunity Fund £20M (February 2025); UK-wide biotech and life science LP mandate
• LinkedIn: British Business Bank LinkedIn
• Sector Focus: UK biotech, life sciences, deep tech innovation
• Stage Focus: Fund LP (not direct)
• Location: Sheffield with UK-wide coverage
• Website: british-business-bank.co.uk

13. BGF

BGF backs UK and Irish growth-stage companies and co-invested in Enhanced Genomics' extended Series A in 2026 alongside Parkwalk. They deploy £3B over five years and have an active Cambridge healthtech pipeline. BGF is the right investor for Cambridge biotech companies with £1M+ ARR or a validated clinical asset.

• Recent Deals: Enhanced Genomics Series A extension (2026); £3B five-year deployment plan; Cambridge healthtech pipeline
• LinkedIn: BGF LinkedIn
• Sector Focus: Biotech scale-ups, Cambridge healthtech, life science growth
• Stage Focus: Growth (Series A and beyond)
• Location: UK-wide with Cambridge East England coverage
• Website: bgf.co.uk

14. Octopus Ventures

Octopus Ventures deploys £200M+ annually and made 18 investments in 2025. Their health and biotech team is active in Cambridge deep tech. They have a dedicated £40M deep tech pre-seed fund. Cambridge biotech founders building AI-driven diagnostics or health tools should include Octopus in their seed or Series A process.

• Recent Deals: 18 investments in 2025; £40M deep tech pre-seed fund; Infinitopes investment (January 2026)
• LinkedIn: Octopus Ventures LinkedIn
• Sector Focus: Health, biotech, deep tech, AI-driven diagnostics
• Stage Focus: Pre-seed to growth
• Location: London with Cambridge deal flow
• Website: octopusventures.com

How to get a warm intro to a Cambridge biotech VC

Cambridge biotech VCs convert warm intros significantly faster than cold email. The two most effective paths are the Cambridge Investor Day and the Babraham Research Campus network.

Applying to Accelerate@Babraham or Cambridge Enterprise START 3.0 before approaching VCs directly is the fastest way in. Both programmes give you a structured intro to CIC, Parkwalk, and IP Group partners.

Cambridge Angels hosts informal events where Amadeus Capital Partners and Parkwalk partners attend. Getting into their network before your formal raise opens every major Cambridge VC's inbox.

What Cambridge biotech investors look for

Cambridge biotech investors want IP ownership clearly resolved before seed close. Most Cambridge-specific VCs won't term sheet until university IP assignments and co-inventor agreements are signed.

At seed, expect questions about regulatory pathway and mechanism of action. At Series A, you need clinical proof-of-concept or Phase I data, plus a co-investor with name recognition.

Don't claim your therapeutic approach is novel if it's been published without your involvement. Cambridge investors talk to department heads. Dead portfolio companies with no recent deals are red flags.

Use Ellty to track which Cambridge biotech investors open your clinical data section. Those who spend time on your mechanism of action slides are worth following up.

How Cambridge biotech accelerators work

Cambridge has three main entry points for early-stage biotech: Cambridge Enterprise START 3.0, Accelerate@Babraham, and Deep Tech Labs. Each feeds directly into the CIC, Parkwalk, and IP Group investor networks.

START 3.0 invests £30K with no equity taken until you raise externally. Accelerate@Babraham provides lab space, mentorship, and investor access on the Babraham Research Campus. Deep Tech Labs is backed by ARM and the University of Cambridge.

Read about virtual data room features to understand what documentation structure Cambridge VCs and accelerators expect. Organised materials in a data room signal readiness before you've said a word.